Ossiam Makes New Investment in Illumina, Inc. (NASDAQ:ILMN)
Ossiam bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 169 shares of the life sciences company’s stock, valued at approximately $62,000.
Other large investors have also modified their holdings of the company. Next Capital Management LLC bought a new position in Illumina in the 2nd quarter valued at about $25,000. Strategy Asset Managers LLC bought a new position in Illumina in the 1st quarter valued at about $26,000. Mizuho Securities Co. Ltd. bought a new position in Illumina in the 1st quarter valued at about $37,000. Harel Insurance Investments & Financial Services Ltd. bought a new position in Illumina in the 2nd quarter valued at about $37,000. Finally, Trustcore Financial Services LLC bought a new position in Illumina in the 2nd quarter valued at about $44,000. 90.92% of the stock is currently owned by institutional investors.
Several equities analysts have recently weighed in on ILMN shares. Piper Jaffray Companies reduced their price objective on shares of Illumina from $382.00 to $348.00 and set an “overweight” rating for the company in a research report on Tuesday, July 30th. UBS Group raised their price objective on shares of Illumina from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Canaccord Genuity lowered shares of Illumina from a “buy” rating to a “hold” rating and reduced their price objective for the company from $330.00 to $300.00 in a research report on Tuesday, July 30th. Cowen reduced their price objective on shares of Illumina from $380.00 to $320.00 and set an “outperform” rating for the company in a research report on Friday, July 12th. Finally, ValuEngine upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $330.92.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. The business had revenue of $838.00 million during the quarter, compared to analyst estimates of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The firm’s revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.43 earnings per share. Sell-side analysts forecast that Illumina, Inc. will post 6.04 earnings per share for the current fiscal year.
In related news, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $349.28, for a total transaction of $3,492,800.00. Following the transaction, the senior vice president now owns 65,994 shares of the company’s stock, valued at $23,050,384.32. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Robert P. Ragusa sold 2,230 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $293.09, for a total transaction of $653,590.70. Following the transaction, the senior vice president now directly owns 10,685 shares in the company, valued at approximately $3,131,666.65. The disclosure for this sale can be found here. Insiders sold 56,198 shares of company stock valued at $17,773,470 over the last three months. 0.38% of the stock is owned by insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: Sell-Side Analysts
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.